keyword
MENU ▼
Read by QxMD icon Read
search

Extrapyramidal symptoms (EPS)

keyword
https://read.qxmd.com/read/30695288/prevalence-of-and-risk-factors-for-extrapyramidal-side-effects-of-antipsychotics-results-from-the-national-face-sz-cohort
#1
David Misdrahi, Arnaud Tessier, Antoine Daubigney, Wassilios G Meissner, Franck Schurhoff, Laurent Boyer, Ophélia Godin, Ewa Bulzacka, Bruno Aouizerate, Meja Andrianarisoa, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau-Boudet, Thierry D'Amato, Caroline Dubertret, Julien Dubreucq, Catherine Faget-Agius, Christophe Lançon, Jasmina Mallet, Christine Passerieux, Romain Rey, Aurélie Schandrin, Mathieu Urbach, Pierre Vidailhet, Pierre-Michel Llorca, Guillaume Fond
BACKGROUND: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing. OBJECTIVE: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia...
January 8, 2019: Journal of Clinical Psychiatry
https://read.qxmd.com/read/30638073/the-burden-of-tardive-dyskinesia-secondary-to-antipsychotic-medication-use-among-patients-with-mental-disorders
#2
Joseph McEvoy, Tyson Park, Traci Schilling, Emi Terasawa, Rajeev Ayyagari, Benjamin Carroll
OBJECTIVE: To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications Methods: Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder, or bipolar disorder were extracted from a Medicaid claims database. Separate cohorts of TD patients with and without other EPS ("TD + EPS" and "TD non-EPS") were constructed and matched to patients in a non-TD/EPS control cohort at a ∼1:5 ratio...
January 13, 2019: Current Medical Research and Opinion
https://read.qxmd.com/read/30582129/ziprasidone-haloperidol-and-clonazepam-intramuscular-administration-in-the-treatment-of-agitation-symptoms-in-chinese-patients-with-schizophrenia-a-network-meta-analysis
#3
Liang Su, Zheng Lu, Shenxun Shi, Yifeng Xu
Background: Agitation is very common in patients with acute stage schizophrenia, and injection of antipsychotics and clonazepam is widely used. Network meta-analysis of these comparisons among three injection treatments has been seldom reported. Aim: To compare the efficacy and safety of various injections for agitation symptoms in Chinese patients with schizophrenia. Methods: Searches were made in PubMed, Embase and Web of Knowledge, Cochrane Library, Wanfang data, CNKI, SinoMed and VIP databases up to 18 February 2018...
2018: General psychiatry
https://read.qxmd.com/read/30569017/leigh-syndrome-followed-by-parkinsonism-in-an-adult-with-homozygous-c-626c-t-mutation-in-mtfmt
#4
Dimitri M Hemelsoet, Arnaud V Vanlander, Joél Smet, Elise Vantroys, Marjan Acou, Ingeborg Goethals, Tom Sante, Sara Seneca, Bjorn Menten, Rudy Van Coster
Objective: To report the clinical, radiologic, biochemical, and molecular characteristics in a 46-year-old participant with adult-onset Leigh syndrome (LS), followed by parkinsonism. Methods: Case description with diagnostic workup included blood and CSF analysis, skeletal muscle investigations, blue native polyacrylamide gel electrophoresis, whole exome sequencing targeting nuclear genes involved in mitochondrial transcription and translation, cerebral MRI, 123I-FP-CIT brain single-photon emission computed tomography (SPECT), and C-11 raclopride positron emission tomography (PET)...
December 2018: Neurology. Genetics
https://read.qxmd.com/read/30546092/improving-pharmacogenetic-prediction-of-extrapyramidal-symptoms-induced-by-antipsychotics
#5
Daniel Boloc, Anna Gortat, Jia Qi Cheng-Zhang, Susana García-Cerro, Natalia Rodríguez, Mara Parellada, Jeronimo Saiz-Ruiz, Manolo J Cuesta, Patricia Gassó, Amalia Lafuente, Miquel Bernardo, Sergi Mas
In previous work we developed a pharmacogenetic predictor of antipsychotic (AP) induced extrapyramidal symptoms (EPS) based on four genes involved in mTOR regulation. The main objective is to improve this predictor by increasing its biological plausibility and replication. We re-sequence the four genes using next-generation sequencing. We predict functionality "in silico" of all identified SNPs and test it using gene reporter assays. Using functional SNPs, we develop a new predictor utilizing machine learning algorithms (Discovery Cohort, N = 131) and replicate it in two independent cohorts (Replication Cohort 1, N = 113; Replication Cohort 2, N = 113)...
December 13, 2018: Translational Psychiatry
https://read.qxmd.com/read/30529195/antipsychotics-induced-metabolic-alterations-recounting-the-mechanistic-insights-therapeutic-targets-and-pharmacological-alternatives
#6
REVIEW
Raghunath Singh, Yashika Bansal, Bikash Medhi, Anurag Kuhad
Atypical antipsychotics (AAPs) are the drug of choice in the management of mental illnesses by virtue of their advantage over typical antipsychotics i.e. least tendency of producing extrapyramidal motor symptoms (EPS) or pseudoparkinsonism. Despite the clinical efficacy, AAPs produces troublesome adverse effects, particularly hyperphagia, hyperglycemia, dyslipidemia weight gain, diabetes mellitus, insulin resistance and QT prolongation which further develops metabolic and cardiac complications with subsequent reduction in life expectancy, poor patient compliance, and sudden death...
February 5, 2019: European Journal of Pharmacology
https://read.qxmd.com/read/30515916/baseline-imbalances-and-clinical-outcomes-of-atypical-antipsychotics-in-dementia-a-meta-epidemiological-study-of-randomized-trials
#7
Tessa A Hulshof, Sytse U Zuidema, Peter J K van Meer, Christine C Gispen-de Wied, Hendrika J Luijendijk
OBJECTIVES: To assess baseline imbalances in placebo-controlled trials of atypical antipsychotics in dementia, and their association with neuropsychiatric symptoms (NPS), extrapyramidal symptoms (EPS), and mortality. METHOD: We searched for trials in multiple sources. Two reviewers extracted baseline characteristics and outcomes per treatment group. We calculated direction, range, pooled mean, and heterogeneity in the baseline differences, and used meta-regression for the relationship with the outcomes...
December 4, 2018: International Journal of Methods in Psychiatric Research
https://read.qxmd.com/read/30498351/time-to-onset-and-time-to-resolution-of-extrapyramidal-symptoms-in-patients-with-exacerbated-schizophrenia-treated-with-3-monthly-vs-once-monthly-paliperidone-palmitate
#8
Maju Mathews, Isaac Nuamah, Adam J Savitz, David W Hough, Dean Najarian, Edward Kim, Srihari Gopal
Objective: The aim of this study was to evaluate the safety of 3-monthly paliperidone palmitate (PP3M) vs once-monthly paliperidone palmitate (PP1M) treatment with regard to extrapyramidal symptom (EPS)-related treatment-emergent adverse events (TEAEs) in patients with schizophrenia, previously stabilized on PP1M treatment. Patients and methods: Data on overall incidence, time to onset (TTO), and time to resolution (TTR) of EPS-related TEAEs (overall, subclasses such as dyskinesia, dystonia, hyperkinesia, parkinsonism, and tremor) from a randomized double-blind (DB) non-inferiority study were compared between PP3M and PP1M...
2018: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/30410159/extrapyramidal-symptoms-resulting-from-risperidone-use-in-a-four-year-old-child-a-case-report
#9
Ehsan Elahi, Umar Zia, Omar Akhlaq Bhutta, Sidrah Andleeb
Extrapyramidal symptoms (EPS) are the major constraint in the use of antipsychotic agents. It is usually forewarned whenever therapy with these agents is considered. In this case, we present a child diagnosed with relapsed Wilm's tumour, who developed EPS just after a short duration of initiation of risperidone prescribed as an appetite stimulant. The patient became symptom free after management and risperidone was discontinued. Although risperidone has been approved to treat different indications in adolescents and children, scarce scientific evidence and our case report, are suggestive of further studies to establish safety of risperidone use in preschool children...
November 2018: JPMA. the Journal of the Pakistan Medical Association
https://read.qxmd.com/read/30234886/characterization-of-neurological-soft-signs-in-a-brazilian-sample-of-stable-patients-with-schizophrenia
#10
Vinicius Sousa Pietra Pedroso, Antônio Lúcio Teixeira, João Vinícius Salgado
INTRODUCTION: Neurological soft signs (NSS) have been considered one of the target features and a potential endophenotype for schizophrenia. The present study aimed to characterize NSS in a sample of patients with chronic schizophrenia and to compare them with healthy control individuals. METHODS: In this study, we evaluated the presence of NSS in a sample of stable patients (n = 24) diagnosed with schizophrenia according to DSM-IV criteria, recruited at the Schizophrenia Outpatient Clinic of Instituto Raul Soares, Belo Horizonte, state of Minas Gerais, southeastern Brazil...
July 2018: Trends in Psychiatry and Psychotherapy
https://read.qxmd.com/read/30185173/comparative-efficacy-and-safety-between-amisulpride-and-olanzapine-in-schizophrenia-treatment-and-a-cost-analysis-in-china-a-systematic-review-meta-analysis-and-cost-minimization-analysis
#11
Peng Men, Zhanmiao Yi, Chaoyun Li, Shuli Qu, Tengbin Xiong, Xin Yu, Suodi Zhai
BACKGROUND: Amisulpride was introduced into China in 2010 as a second-generation atypical antipsychotic, while olanzapine has been on the market since 1999 as one of the leading treatments for schizophrenia in China. Since more Chinese patients are gaining access to amisulpride, the study aims to compare the efficacy, safety, and costs between amisulpride and olanzapine for schizophrenia treatment in China. METHODS: PubMed, Embase, the Cochrane library, China National Knowledge Infrastructure (CNKI) and WanFang database were systematically searched for randomized controlled trials (RCTs) up to July 2018...
September 5, 2018: BMC Psychiatry
https://read.qxmd.com/read/30109845/long-term-safety-and-tolerability-of-aripiprazole-lauroxil-in-patients-with-schizophrenia
#12
Henry A Nasrallah, Ralph Aquila, Yangchun Du, Arielle D Stanford, Amy Claxton, Peter J Weiden
OBJECTIVE: Safety and tolerability of long-term treatment with the long-acting antipsychotic aripiprazole lauroxil (AL) were evaluated in patients with schizophrenia. METHODS: This was an international, multicenter, phase 3, 52-week safety study of 2 fixed doses of AL (441 mg or 882 mg intramuscular every 4 weeks). Safety endpoints included adverse events (AEs) and extrapyramidal symptoms (EPS) including akathisia, injection-site reactions (ISRs), and clinically relevant changes in metabolic and endocrine values...
August 15, 2018: CNS Spectrums
https://read.qxmd.com/read/29924506/clinical-predictors-of-extrapyramidal-symptoms-associated-with-aripiprazole-augmentation-for-the-treatment-of-late-life-depression-in-a-randomized-controlled-trial
#13
Jonathan H Hsu, Benoit H Mulsant, Eric J Lenze, Marcos Sanches, Jordan F Karp, Charles F Reynolds, Daniel M Blumberger
OBJECTIVE: Augmentation with aripiprazole is an effective pharmacotherapy for treatment-resistant late-life depression (LLD). However, aripiprazole can cause extrapyramidal symptoms (EPS) such as akathisia and parkinsonism; these symptoms are distressing and can contribute to treatment discontinuation. We investigated the clinical trajectories and predictors of akathisia and parkinsonism in older patients receiving aripiprazole augmentation for treatment-resistant LLD. METHODS: Between 2009 and 2013, depressed older adults who did not remit with venlafaxine were randomized to aripiprazole or placebo in a 12-week trial...
June 19, 2018: Journal of Clinical Psychiatry
https://read.qxmd.com/read/29920656/antipsychotics-for-treatment-of-delirium-in-hospitalised-non-icu-patients
#14
REVIEW
Lisa Burry, Sangeeta Mehta, Marc M Perreault, Jay S Luxenberg, Najma Siddiqi, Brian Hutton, Dean A Fergusson, Chaim Bell, Louise Rose
BACKGROUND: Guidelines suggest limited and cautious use of antipsychotics for treatment of delirium where nonpharmacological interventions have failed and symptoms remain distressing or dangerous, or both. It is unclear how well these recommendations are supported by current evidence. OBJECTIVES: Our primary objective was to assess the efficacy of antipsychotics versus nonantipsychotics or placebo on the duration of delirium in hospitalised adults. Our secondary objectives were to compare the efficacy of: 1) antipsychotics versus nonantipsychotics or placebo on delirium severity and resolution, mortality, hospital length of stay, discharge disposition, health-related quality of life, and adverse effects; and 2) atypical vs...
June 18, 2018: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/29802039/efficacy-acceptability-and-tolerability-of-antipsychotics-in-children-and-adolescents-with-schizophrenia-a-network-meta-analysis
#15
REVIEW
Marc Krause, Yikang Zhu, Maximilian Huhn, Johannes Schneider-Thoma, Irene Bighelli, Anna Chaimani, Stefan Leucht
Children and adolescents with schizophrenia are a particularly vulnerable group. Thus, we integrated all the randomized evidence from the available antipsychotics used for this subgroup by performing a network-meta-analysis and pairwise meta-analysis using a random-effects model. We searched multiple databases up to Nov 17, 2016 (final update search in PubMed: Dec 12, 2017). The primary outcome was efficacy as measured by overall change/endpoint in symptoms of schizophrenia. Secondary outcomes included positive and negative symptoms, response, dropouts, quality of life, social functioning, weight gain, sedation, prolactin, extrapyramidal side effects (EPS) and antiparkinsonian medication...
June 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/29780333/neurological-soft-signs-spontaneous-and-treatment-emergent-extrapyramidal-syndromes-in-black-africans-with-first-episode-schizophrenia
#16
Akin Ojagbemi, Bonga Chiliza, Toyin Bello, Laila Asmal, Oluyomi Esan, Robin Emsley, Oye Gureje
Background: Very little is known about the relationship between spontaneous and treatment-induced motor syndromes in Africans with first episode schizophrenia. Objective: We investigated the association between spontaneous NSS and EPS, with treatment-induced EPS in a homogenous sample of Black Africans with first episode schizophrenia. Methods: We examined Xhosa (South Africa) and Yoruba (Nigeria) patients, using the Neurological Evaluation Scale and extrapyramidal symptoms scale before and at 3 months after exposure to low dose flupenthixol decanoate...
2018: Frontiers in Psychiatry
https://read.qxmd.com/read/29686794/risperidone-induced-angioedema-with-concurrent-eps-symptoms-a-case-report-and-review-of-literature
#17
Gursharan Singh Samra, Saumitra Kant, Robert Chow
Angioedema has recently been reported as a side effect associated with the antipsychotic risperidone. We report a case of dystonia with concurrent angioedema due to risperidone. A 40-year-old male with a history of schizophrenia was started on 3 mg of risperidone BID and developed perioral and periorbital edema along with increased muscle rigidity and hand tremor within 24 h of initial administration. His symptoms abated after cessation of risperidone and intravenous administration of corticosteroids and antihistamine...
2018: Journal of Community Hospital Internal Medicine Perspectives
https://read.qxmd.com/read/29516413/interplay-between-adenosine-receptor-antagonist-and-cyclooxygenase-inhibitor-in-haloperidol-induced-extrapyramidal-effects-in-mice
#18
Devinder Arora, Jayesh Mudgal, Madhavan Nampoothiri, Sanchari Basu Mallik, Manas Kinra, Susan Hall, Shailendra Anoopkumar-Dukie, Gary D Grant, Chamallamudi Mallikarjuna Rao
Antipsychotic drugs are the mainstay of psychotic disorders. The 'typical' antipsychotic agents are commonly employed for the positive symptoms of schizophrenia, though at an expense of extrapyramidal side effects (EPS). In the present study, we employed haloperidol (HP)-induced catalepsy model in mice to evaluate the role of adenosine receptor antagonist and cyclooxygenase (COX) enzyme inhibitor in the amelioration of EPS. HP produced a full blown catalepsy, akinesia and a significant impairment in locomotion and antioxidant status...
August 2018: Metabolic Brain Disease
https://read.qxmd.com/read/29433934/evidence-based-review-of-pharmacotherapy-for-acute-agitation-part-2-safety
#19
Leslie S Zun
BACKGROUND: The management of acute agitation in the emergency department often requires the administration of rapid-acting antipsychotic agents. However, there are few comparative studies and little guidance regarding the risks associated with use of such drugs in the acute setting. OBJECTIVE: This structured evidence-based review compared the safety of antipsychotic pharmacotherapies for acute agitation using data from randomized controlled trials identified by a literature search of the PubMed database...
April 2018: Journal of Emergency Medicine
https://read.qxmd.com/read/29092658/an-unexpected-circumstance-acute-dystonic-reaction-in-the-setting-of-clozapine-administration
#20
Alexander Morris Kaplan, William Bradly Pitts, Iqbal Ahmed
Clozapine is a second-generation antipsychotic typically reserved for refractory psychotic disorders due to its high-risk side effect profile to include agranulocytosis, with its attendant need for regular blood draws. While reports of extrapyramidal symptoms (EPS), including acute dystonic reactions, are exceedingly rare, we present the case of a 44-year-old male with a long-standing history of treatment-resistant schizoaffective disorder and no history of EPS who experienced an acute buccal dystonic reaction in the setting of clozapine initiation and discontinuation of depot and oral risperidone...
January 1, 2017: Journal of Pharmacy Practice
keyword
keyword
170805
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"